When Is the Right Time to Start KRYSTEXXA for Gout Treatment?

By Dr. Anna Zezon, Board-Certified Rheumatologist, Arthritis & Rheumatic Care

If you’ve been living with gout for years — cycling through flare after flare, watching hard, chalky deposits (called tophi) build up around your joints, and wondering why nothing seems to bring lasting relief — you’re not alone, and you’re not out of options. One question I hear often in my practice is: Is KRYSTEXXA better than allopurinol for gout? The honest answer is: it depends on where you are in your gout journey. Here’s how I think about it, and how I decide with my patients when it’s time to make the switch.

Allopurinol is still the right place to start — for most patients

Allopurinol is a first-line medication for a reason. For the majority of people with gout, it does exactly what it needs to do: lower uric acid gradually and keep flares under control over time. I reach for KRYSTEXXA rarely, and only when allopurinol has genuinely stopped being enough.

So when does it make sense to consider KRYSTEXXA?

In my practice, KRYSTEXXA is reserved for gout that simply isn’t responding — patients who continue to have recurrent flares despite being on a therapeutic dose of allopurinol, and especially patients who have developed tophaceous gout, where uric acid crystals have accumulated into visible deposits, often at the elbows, ankles, or other joints.

If you’re dealing with:

• Recurrent flares that keep happening even though you’re on an appropriate, therapeutic dose of allopurinol

• Visible tophi that aren’t shrinking

• Pain and disability from gout that is genuinely affecting your quality of life

— that’s when I start the conversation about KRYSTEXXA. It isn’t a first-choice treatment, and it isn’t the right fit for mild gout. But for patients who meet these criteria, it can be the thing that finally changes the picture.

Why KRYSTEXXA can succeed where allopurinol has plateaued

The difference comes down to how far each medication can bring uric acid down. Allopurinol lowers uric acid, but typically not to the very low levels needed to rapidly dissolve existing tophi — that process, left to allopurinol alone, can take five to eight years, if it happens at all.

KRYSTEXXA works differently. It drives uric acid down to undetectable levels, which allows existing tophi to dissolve much more rapidly. Instead of years, we’re often talking about a meaningfully shorter course of treatment to see those deposits disappear.

A patient’s story

One of my patients had gone undiagnosed for years. By the time he came to see me, he had developed tophaceous gout at his right ankle and both elbows, with recurrent flares that had become disabling — the pain and the unpredictability of it had taken a real toll on his quality of life.

We started him on KRYSTEXXA. He began improving even before finishing the full course, and after about a year and a half of treatment, his tophi had completely melted away. He stopped having flares, and his quality of life improved significantly. Stories like his are exactly why I think it’s so important for patients with long-standing, treatment-resistant gout to know this option exists.

How we keep it safe

KRYSTEXXA requires careful monitoring, and that’s something we take seriously. Every patient is tested for G6PD deficiency before starting. We also check uric acid levels before every single infusion — as long as those pre-infusion levels remain undetectable, we know the body hasn’t formed antibodies against the medication. Giving KRYSTEXXA alongside immune-modulating pretreatment also significantly lowers the rate of infusion reactions, which is part of our standard protocol.

Who is — and isn’t — a good candidate

KRYSTEXXA isn’t for everyone, and that’s by design. The ideal candidate has tophaceous, refractory gout — not mild or newly diagnosed cases. It also requires real commitment: showing up for lab checks, keeping appointments, and following the infusion schedule closely. When patients are engaged partners in their care, the results can be life-changing.

Our approach

We administer KRYSTEXXA in-house, which means your care team already knows your history, your labs, and you — not just your chart. Treatment like this isn’t something we hand off; we monitor our patients closely at every step and stay available throughout the journey. We built our practice around personalized, attentive care, because we know gout isn’t just a lab value — it’s pain, disability, and quality of life, and we want every patient to feel genuinely supported in getting better.

If you’ve been managing gout for years without real relief — especially if you’re dealing with tophi or flares that won’t quit despite being on allopurinol — it may be time to talk about whether KRYSTEXXA is right for you.

Ready to talk about your options? Call to book a consultation with our team at Arthritis & Rheumatic Care and find out whether KRYSTEXXA could be the next step in your gout treatment: (201) 975-2400

This article is for educational purposes and reflects the clinical experience of Dr. Anna Zezon. It is not a substitute for personalized medical advice — please consult your physician about whether KRYSTEXXA is appropriate for your individual situation.